The proposed bill, H.B. No. 2025-2026, aims to enact section 3902.65 of the Revised Code, which establishes cost-sharing caps for prescription insulin drugs, diabetes devices, and diabetic ketoacidosis devices. Specifically, the bill defines key terms related to these medical necessities, including "prescription insulin drug," "diabetes device," and "diabetic ketoacidosis device." It mandates that health plan issuers cannot require cost-sharing that exceeds $35 for a thirty-day supply of covered prescription insulin drugs and $100 for a thirty-day supply of covered diabetes or diabetic ketoacidosis devices.

Additionally, the bill stipulates that these cost-sharing limitations apply regardless of any other cost-sharing requirements that may typically be imposed under a health benefit plan. It also allows health plan issuers the flexibility to reduce a covered person's cost-sharing requirement to amounts lower than those specified in the bill. This legislation is designed to alleviate the financial burden on individuals managing diabetes and related conditions by ensuring more affordable access to essential medications and devices.